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EDITORIAL REVIEW
A systematic review of definitions of extreme
phenotypes of HIV control and progression
Deepti Gurdasania,b, Louise Ilesa,b, David G. Dillona,b,
Elizabeth H. Younga,b, Ashley D. Olsonc, Vivek Naranbhaid,e,
Sarah Fidlerf, Effrossyni Gkrania-Klotsasg, Frank A. Posth,
Paul Kellama,i, Kholoud Porterc, Manjinder S. Sandhua,b,
on behalf of the UK HIV Genomics Consortium
The study of individuals at opposite ends of the HIV clinical spectrum can provide
invaluable insights into HIV biology. Heterogeneity in criteria used to define these
individuals can introduce inconsistencies in results from research and make it difficult
to identify biological mechanisms underlying these phenotypes. In this systematic
review, we formally quantified the heterogeneity in definitions used for terms referring
to extreme phenotypes in the literature, and identified common definitions and
components used to describe these phenotypes. We assessed 714 definitions of HIV
extreme phenotypes in 501 eligible studies published between 1 January 2000 and
15 March 2012, and identified substantial variation among these. This heterogeneity in
definitions may represent important differences in biological endophenotypes and
clinical progression profiles of individuals selected by these, suggesting the need for
harmonized definitions. In this context, we were able to identify common components
in existing definitions that may provide a framework for developing consensus
definitions for these phenotypes in HIV infection.
 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2014, 28:149–162
Keywords: definitions, elite controllers, extreme-trait designs, HIV, HIV
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Introduction
Individuals with HIV infection show variable rates of
disease progression and viral control. Whereas some
subgroups of individuals control infection very well and
remain asymptomatic for several years, others show rapid
immunological and clinical progression. A number of
terms have been used to describe individuals at these
extremes of the clinical spectrum, including ‘long-term
nonprogressors’ (LTNPs) [1–5], ‘elite controllers’ [6,7],
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‘slow progressors’ [8–10], ‘HIV controllers’ (HICs) [11],
‘viremic controllers’ [1], ‘noncontrollers’ [12], and ‘rapid
progressors’ [13–15]. These terms represent extremes
within the virological and clinico-immunological range of
disease, with LTNPs and rapid progressors lying on oppo-
site extremes of the clinico-immunological distribution,
and elite controllers and noncontrollers lying on opposite
ends of the spectrum of viral control. The study of these
individuals has provided valuable insights into the biology
and pathogenesis of disease control and progression
[5,16,17]. Indeed, elite controllers have been regarded as
a natural model for disease control, and understanding the
underlying biological mechanisms of this phenomenon
could provide novel therapeutic targets [17,18].
Although these groups have been the focus of intense
study, there is no consistency in how they have been
defined. Studies suggest that different definitions may
select for groups with varying clinical outcomes, and
represent different biological endophenotypes [1,14,19].
This variability in definitions also has important
implications for the design of future biological research
in HIVand for the interpretation of results from existing
literature. Recommendations for consensus definitions
are needed. To examine variability in these definitions,
we conducted a systematic review of the literature. Here,
we describe heterogeneity in the definitions used,
and identify common definitions that may provide a
framework for developing consensus definitions for
extreme HIV clinical phenotypes.
Methods
Search strategy
This systematic review was conducted and reported in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [20]. We used a combination of MeSH and
non-MeSH terms representing extremes of virological
and clinical progression in HIV in PubMed, and reviewed
abstracts for all articles available between 1 January 2000
and 15 March 2012 (Fig. 1). Terms representing extremes
of disease progression and control were included in the
search strategy, as shown in Fig. 1. A total of 1639 abstracts
were reviewed in order to shortlist relevant publications
(Fig. 1, Supplementary Data 1, http://links.lww.com/
QAD/A411). We further reviewed the full-text articles if
the abstract or title mentioned an extreme phenotype
term for disease progression or control in HIV infection
and pertained to HIV infection in human adults. Extreme
phenotypes in both HIV-1 and HIV-2 infection were
considered for the purposes of this review. Articles were
excluded if therewas nomention of disease progression or
control in the abstract or title, or if extreme phenotype
definitions applied to children (<18 years of age) or to
studies in animals. Articles were also reviewed if it was
unclear whether they met the inclusion or exclusion
criteria for the analysis.
On reviewing 1639 abstracts, we identified 730 articles
for full-text review, and 501 studies were included in the
final analysis (Fig. 1, Supplementary Data 2, http://
links.lww.com/QAD/A412). Full-text articles were
reviewed for terms referring to extreme phenotypes in
HIV infection, and definitions were entered into a
database. We listed terms that described extremes of the
clinical spectrum in HIV infection through this review.
These included words and phrases used to describe
extreme groups in each article, such as ‘LTNPs’, ‘elite
controllers’, ‘slow progressors’, ‘viremic controllers’,
‘rapid progressors’, or ‘noncontrollers’ (Table 1). These
phrases will hereby be referred to as ‘terms’, and represent
variously defined phenotypes of HIV control and
progression. The set of clinical and immunological
criteria used to describe the terms in each study are
referred to as ‘definitions’ (Table 2). The data obtained
using the search strategy were independently reviewed by
two investigators (DG and LI) to identify articles for
inclusion and to assess observer bias. Data obtained by the
two investigators were then synthesized and collated. Any
discrepancies in results were resolved by a consensus
discussion. The database was examined for any duplicate
definitions and these were deleted.
Data retrieval
Definitions, as described above, were collated on an
electronic database. Definitions were only included if they
incorporated at least one quantitative element and
pertained to extreme phenotypes in the context of the
natural course of HIV infection. Purely conceptual defini-
tions of phenotypes without any quantitative element and
definitions pertaining to extremes of viral or immuno-
logical control following antiretroviral treatment were not
included in the analysis. However, definitions were
included if they referred to extremes in the natural
progression of HIV infection or viral control, even if they
did not explicitly specify individuals being antiretroviral
therapy (ART)-naive, as long as definitions did not pertain
specifically to treatment-related viral control/disease
progression phenotypes. Articles reviewing HIV pheno-
types, listing several definitions, were not included. Studies
describing case series with no defining criteria were not
included in the analysis (Fig. 1, Supplementary Data 2,
http://links.lww.com/QAD/A412).
Whenmore than one definition was applied to a term, we
listed this as two separate definitions in the database.
Conversely, if more than one term was used to describe a
group of individuals, definitions were listed under all
terms used to refer to the individuals in the study.
Therefore, the number of definitions may be different
from the number of studies listed, as more than one term
may appear in a single study and/or more than one
definition may apply to a single term in a study. For
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example, in one study, the terms ‘LTNPs’ and ‘slow
progressors’ were used synonymously, and were defined as
HIV-infected individuals whomaintain CD4þ cell counts
above 500/ml for at least 10 years after seroconversion or
suppress viral replication to levels of HIV-1-RNA below
300 copies/ml and maintain CD4þ cell counts of at least
1000/ml for at least 6 years [21]. In this case, maintenance
of CD4þ cell counts above 500 cells/ml for more than 10
years following seroconversion, and suppression of viral
loads to below 300 copies/ml with maintenance of CD4þ
cell counts above 1000 cells/ml for 6 years, were
considered as separate independent definitions of long-
term nonprogression/slow progression. In addition, both
definitions were listed under the terms LTNPs and
slow progressors separately, as both terms were used to
describe this group. Thus, although these definitions
pertained to one study, they were included as four
separate data points in the review, two for LTNPs and two
for slow progressors. Lists of collated definitions for
all terms can be found in Supplementary Data 3 and
4, http://links.lww.com/QAD/A414, http://links.lww.
com/QAD/A413.
Data synthesis
Of 1639 papers examined, 501 articles included definitions
of terms used to describe extremes of disease progression or
viral control. We listed all terms applying to definitions of
extreme groups in the clinical/virological spectrum of
HIV, and examined definitions within these groups. For
the purposes of listing definitions, terms representing
similar extreme groups were collapsed as shown in Table 1
and Fig. 2. For example, the term ‘slow progressors’
encompasses the terms ‘slow progressors’ and ‘long-term
slow progressors’, and the term ‘elite controllers’ encom-
passes the terms ‘elite controllers’ and ‘elite suppressors’.
Table 1 describes these individual terms, their frequency,
and the terms collapsed under generic term labels.
To facilitate comparison of definitions, and explore
heterogeneity among definitions and terms, we collapsed
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Terms input into pubmed:
“HIV long-term survivors”[Mesh] or long-term nonprogress*[title/abstract] or long-term non-
progress*[title/abstract] or long-term non-progress*[title/abstract] or slow progress*[title/abstract] or
LTNP[title/abstract] or elite controller[title/abstract] or elite control[title/abstract] or viral
control*[title/abstract] or virological control*[title/abstract] or viremic control*[title/abstract] or viraemic
control*[title/abstract] or rapid progress*[title/abstract] or chronic progress*[title/abstract] or typical
progress*[title/abstract] or accelerated progress*[title/abstract] or fast progress*[title/abstract] or non-
controller*[title/abstract] or non controller*[title/abstract] or controller*[title/abstract]
and
[Mesh] or HIV[title/abstract] or AIDS[title/abstract] or acquired immunodeficiency
syndrome[title/abstract] or “acquired immunodeficiency syndrome”[Mesh]
Limits: only articles after 1st January 2000 until 15th March 2012
1639 article abstracts reviewed
Article not in English: 75
Abstract not available: 18
No mention of extremes of progression or control in
abstract: 665
Extreme phenotypes defined in children: 83
Animal studies: 68
Full text not available: 18
No definition provided: 170
Conceptual definition only (no quantitative element): 25
Treatment-related extremes examined: 6
Review of many definitions: 4
Extreme phenotypes defined in children: 4
Animal studies: 2
730 potentially eligible studies: review full text
501 studies included
Fig. 1. Search strategy.
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2Table 1. Frequency of occurrence of terms used to describe extreme phenotypes in HIV in the literature.
Slow progression No. Viral control No.
Slow progression- viral
control hybrid No. Rapid progressor No. Noncontroller No.
Long-term nonprogressor
(LTNP)a
264 Controller (C)d 8 Long-term nonprogressor-elite
controller (LTNP-EC)g
5 Fast progressor (FP)h 11 High viral load individual 1
Clinical LTNP (CLTNP)a 1 HIV controller (HIC)d 46 Elite-LTNP (E-LTNP)g 1 Rapid progressor (RP)h 79 Medium-high viral
load individual
2
Slow progressor (SP)b 70 Elite controller (EC)e 103 Long-term nonprogressor-viral
controller (LTNP-VC)
1 Super fast progressor (SFP) 1 Noncontroller (NC) 16
Long-term slow progressor
(LTSP)b
1 Elite suppressor (ES)e 14 Long-term nonprogressor-controller
(LTNP-C)
1 Accelerated progressor (AP) 1 Viremic individual (VI) 3
Long-term survivor (LTS) 20 Natural viral suppressor
(NVS)f
4 Nonprogressor-elite controller
(NP-EC)
1
Long-term asymptomatic (LTA) 4 Viral suppressor (VS)f 1 Viremic nonprogressor (VNP) 2
Nonprogressor (NP)c 12 Low viral load individual
(LVLI)
2 Viremic noncontrollers (VNC) 1
Clinical nonprogressor (CNP)c 1 Relative controller (RC) 2
Slow progressor with robust
replication (SP-RR)
1 Viremic controller (VC) 32
Aviremic individual (AVI) 2
aCollated under the term ‘long-term nonprogressors’.
bCollated under the term ‘slow progressors’.
cCollated under the term ‘nonprogressor’.
dCollated under the term ‘HIV controller’.
eCollated under the term ‘elite controller’.
fCollated under the term ‘natural virus suppressor’.
gCollated under the term ‘elite-LTNP’.
hCollated under the term ‘rapid progressor’.
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definitions that contained common components and
component thresholds for clinical and immunological
criteria under each term (Table 3). These broad
components were identified by reviewing all definitions
for each term. The term ‘component’ here refers to
categories of common clinical and immunological
criteria used in definitions, and ‘component threshold/
categories’ refers to the thresholds or categories used for
these components in each definition (Table 2). For
example, key components identified for definitions of
LTNPs were duration of follow-up, CD4þ cell count
threshold, HIV-RNA thresholds, CD4þ cell slopes and
clinical criteria, such as asymptomatic or AIDS-free
follow-up (Table 3). To identify unique definitions for
each term, we then collapsed definitions based on each
distinct combination of components and component
thresholds or categories, with a view to grouping broadly
similar definitions. We only collapsed definitions
for terms for which we had identified more than
10 definitions in the literature. When different duration
Extreme phenotypes of HIV control and progression Gurdasani et al. 153
Table 2. Glossary of descriptors used in review.
Definitions
Terms Words or phrases describing extremes of the clinico-immunological and virological
spectrum in HIV infection, e.g., ‘elite controllers’.
Definitions The set of clinical and immunological criteria used to describe the terms in each study. For example,
elite controllers are HIV-infected individuals who suppress plasma HIV-RNA levels to
<50copies/ml without antiretroviral treatment.
Component Broad categories of common clinical and immunological criteria used in definitions. For example,
‘HIV-RNA level’ is a component of definitions for elite controllers
Component threshold/
category
Thresholds or categories for the specific component in each definition. For example, a HIV-RNA
threshold of <50 copies/ml in definitions of elite controllers
Descriptions of HIV extreme phenotypes listed from 501 articles
Collation of terms and definitions in broad groups
Slow progression/viral control extreme:
19 terms
Terms with > 10 definitions:
7 terms
LTNP:
265
definitions
(159
unique)
SP:
(collated
from SP and
LTSP)
71
definitions
(48 unique)
LTS:
20
definitions
(17 unique)
NP:
(collated
from NP
and CNP)
13
definitions
(11 unique)
EC:
(collated
from EC and
ES)
117
definitions
(50 unique)
HIC:
(collated
from HIC
and C)
54
definitions
(30 unique)
VC:
32
definitions
(19 unique)
NC:
16
definitions
(8 unique)
RP:
(collated
from RP
and FP)
90
definitions
(51 unique)
Rapid progression/viral non-control extreme:
7 terms
Terms with > 10 definitions:
2 terms
Slow progression/viral control extreme
26 terms, 600 definitions
Rapid progressionn/viral non-control extreme
8 terms, 114 definitions
Fig. 2. Data synthesis: a process for collapsing and categorizing individual terms and definitions. C, controller; CNP, clinical
nonprogressor; EC, elite controller; ES, elite suppressor; FP, fast progressor; HIC, HIV controller; LTNP, long-term nonprogressor;
LTS, long-term survivor; LTSP, long-term slow progressor; NC, noncontroller; NP, nonprogressor; RP, rapid progressor; SP, slow
progressor; VC, viremic controller.
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thresholds were applied to different components in a
definition (e.g., duration of asymptomatic follow-up,
duration of CD4þ cell level below a threshold), only the
greatest duration was considered, as this would be the
minimum duration of follow-up needed to meet the
criteria for a given definition. When multiple HIV-RNA
assays were used, the assay with the highest threshold for
lower limit of detection was considered.
After collapsing, definitions with a distinct combination
of components and component thresholds/categories
were identified as being unique. The proportion of
unique definitions was calculated for each term. This
proportion reflects the heterogeneity of definitions in
literature. We ranked definitions identified in this way by
frequency of occurrence, and listed the most common
definitions for each term. The salient features of each
definition were listed based on common components
identified across definitions, to describe the most
common components used to define terms referring to
HIV extreme phenotypes in the literature. We also
compared the frequency of component thresholds used in
definitions of different terms, in order to assess the overlap
of components and component thresholds/categories
between definitions of different terms.
Results
On reviewing 501 articles, 600 definitions were listed for
26 terms used to describe slow progression/viral control
extremes in HIV infection and 114 definitions for eight
terms used to define fast progressor/viral noncontrol
extremes in HIV infection (Fig. 2). The various terms
used to describe these extremes in the literature are
outlined in Table 1. Following collapsing of terms under
broad groups, 19 terms for slow progression/viral control
phenotypes and seven terms for rapid progression/
noncontrol phenotypes were examined (Table 1, Fig. 2).
Of the 26 terms listed, only nine terms that included
more than 10 definitions each, were considered for
further analysis (Fig. 2). The most common terms used in
studies of slow progression extremes were ‘LTNP’ (265
instances), followed by ‘slow progressor’ (71 instances;
Table 1), ‘long-term survivor (LTS)’ (20 instances), and
‘nonprogressors’ (13 instances). Common terms used to
describe the extreme of viral control were ‘elite con-
trollers/elite suppressors’ (117 instances), ‘viremic con-
troller’ (32 instances), and ‘HIC/controller’ (54 instances;
Table 1). Fewer terms were identified for the rapid
progression extremes in HIV infection, with 90 instances
of ‘rapid progressors/fast progressors’ (Table 1). For the
extreme of noncontrol of HIV, ‘noncontroller’ was the
commonest term used, with 16 definitions appearing in
the literature.
We also examined the pattern of term usage by time of
publication. We observed a greater diversity of terms used
to describe viral control and noncontrol phenotypes in
the period 2006–2012 as compared to the literature
published between 2000 and 2005 (Fig. 3). Notably,
terms pertaining to viral control phenotypes, such as ‘elite
controller’, ‘HIC’, ‘viremic controller’, and ‘noncon-
troller’ seem to be used almost exclusively from 2006
onward, indicating the more recent interest in viral
control-related phenotypes as compared with clinical
phenotypes of nonprogression or rapid progression in
the literature.
Redundancy of definitions in the literature
The total number of definitions and the number of
unique definitions identified for each term are presented
in Table 4. Heterogeneity in definitions was high, with a
large proportion of definitions being unique for
progression (54–85%) and viral control (43–59%)-related
terms. Unique definitions for all terms can be found in
154 AIDS 2014, Vol 28 No 2
Table 3. Broad components used to collapse definitions of progression and control HIV phenotypes.
Components of slow progression/viral control phenotype
definitions (terms – LTNP, SP, LTS, NP, EC, HIC, and VC)
Components of rapid progression/viral noncontrol
phenotype definitions (terms RP and NC)
Components Component threshold/category Component Component threshold/category
Duration of follow-up Minimum duration of follow-up in years Duration of follow-up Minimum duration of follow-up in years
CD4þ cell count CD4þ cell count threshold in count/ml CD4þ cell endpoint CD4þ cell count threshold in count/ml
HIV-RNA level Plasma HIV-RNA threshold in copies/ml HIV-RNA level Plasma HIV-RNA threshold in copies/ml
Clinical symptoms Asymptomatic/AIDS-free/OI free (yes/no) CD4þ cell slope Numeric threshold of decline in cells/ml per year
CD4þ cell slope Numeric threshold of decline
in cells/ml per year or qualitative
(e.g., ‘stable’ CD4þ cell levels)
AIDS endpoint AIDS endpoint present in definition (yes/no)
Viral blips Threshold for occasional spikes in
HIV-RNA levels allowed
ART endpoint ART endpoint present in definition (yes/no)
Death endpoint Death endpoint present in definition (yes/no)
Seroconversion status Seroconversion status known (yes/no/unspecified)
ART, antiretroviral therapy; EC, elite controllers; HIC, HIV controllers; LTNP, long-term nonprogressors; LTS, long-term survivors; NC,
noncontrollers; NP, nonprogressors; OI, opportunistic infection; RP, rapid progressors; SP, slow progressors; VC, viremic controllers.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Supplementary Tables 1–9, http://links.lww.com/
QAD/A415.
Description of extreme phenotypes in the
literature
Long-term nonprogressors
Of 265 definitions of LTNPs, 159 were unique
when combinations of duration of follow-up, CD4þ
cell thresholds, CD4þ cell slopes, clinical symptoms, and
viral load components were considered. There was
substantial variation in components and component
thresholds (Fig. 4, Supplementary Table 10, http://
links.lww.com/QAD/A415). Duration of follow-up
varied between 1 and 25 years among definitions, with
10 years being the most common duration of follow-up
required (Fig. 4). Although CD4þ cell thresholds were a
prominent feature of LTNP definitions, with 74% of all
definitions including a CD4þ cell threshold criterion,
thresholds showed marked variation across definitions
with a range between 300 and 1000 cells/ml. The most
Extreme phenotypes of HIV control and progression Gurdasani et al. 155
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Fig. 3. Frequency of term usage by calendar period. AP, accelerated progressor; AVI, aviremic individual; C, controller; CLTNP,
clinical long-term nonprogressor; CNP, clinical nonprogressor; EC, elite controller; ES, elite suppressor; FP, fast progressor; HIC,
HIV controller; HVL, high viral load individual; LTA, long-term asymptomatic; LTNP, long-term nonprogressor; LTNP-C, long-
term nonprogressor controller; LTNP-EC, long-term nonprogressor-elite controller; LTNP-VC, long-term nonprogressor-viremic
controller; LTS, long-term survivor; LTSP, long-term slow progressor; LVLI, low viral load individual; MHVL, medium-high viral
load individual; NC, noncontroller; NP, nonprogressor; NVS, natural viral suppressor; RC, relative controller; RP, rapid progressor;
SFP, super fast progressor; SP, slow progressor; VC, viremic controller; VI, viremic individual; VNC, viremic noncontroller; VNP,
viremic nonprogressor; VS, viral suppressor.
Table 4. Proportion of unique definitions within each term.
Phenotype Terms Total number of definitions Unique definitions (%)
Slow progression LTNP 265 159 (60%)
SP 71 48 (69%)
LTS 20 17 (85%)
NP 13 11 (85%)
Viral control EC 117 50 (43%)
HIC 54 30 (56%)
VC 32 19 (59%)
Rapid progression RP 90 51 (54%)
Viral noncontrol NC 16 8 (50%)
EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; LTS, long-term survivor; NC, noncontroller; NP, nonprogressor; RP, rapid
progressor; SP, slow progressor; VC, viremic controller.
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frequent CD4þ cell threshold was 500 cells/ml (Fig. 4,
Supplementary Table 10, http://links.lww.com/QAD/
A415). A component including a HIV-RNA threshold
was less common, with only 36% of definitions including
a viral load criterion. The absence of clinical symptoms
also appeared to be a prominent criterion, with around
58% of definitions including a criterion of being
asymptomatic, without opportunistic infection or
AIDS-free. CD4þ cell slopes were also common features
of definitions, with 31% of definitions including a
criterion for stability of CD4þ cell counts (Fig. 4).
Slow progressors
Of 71 definitions identified for slow progressors, 69%
were unique with respect to the components described
(Table 4). As with LTNP definitions, duration of follow-
up was an important component, with 90% of definitions
including a criterion for minimum duration of follow-up
(Fig. 4). There was marked variation in duration
thresholds, ranging from 10 months to 16 years, the
most frequently appearing threshold being 8 years of
follow-up (Fig. 4, Supplementary Table 10, http://
links.lww.com/QAD/A415). In general, the duration of
follow-up needed to define slow progressors was lower
than that for LTNPs (Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds and
the absence of clinical symptoms were also important
components, with 72 and 52% of definitions including
these, respectively (Fig. 4). As with LTNPs, a CD4þ cell
threshold of 500 cells/ml was most common, with
thresholds ranging from 200 to 1000 cells/ml (Supple-
mentary Table 10, http://links.lww.com/QAD/A415).
The frequency of various component thresholds can be
found in Supplementary Table 10, http://links.lww.com/
QAD/A415. CD4þ cell slope and HIV-RNA thresholds
were less common for these definitions, with only 21 and
20% of definitions including each of these components,
respectively (Fig. 4).
Long-term survivors
Of 20 definitions listed for LTSs, 17 were unique
(Table 4). As expected, duration of follow-up was a
prominent component with 10 years being the most
frequent threshold (Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds were
also prominent components, with 12 definitions includ-
ing a threshold, the commonest being 500 cells/ml
(Table 4). Clinical criteria of symptom/AIDS-free
follow-up were also common with 50% of definitions
including this component (Table 4, Supplementary
156 AIDS 2014, Vol 28 No 2
Slow progression phenotypes
Terms(no. of
definitions)
Components
Duration of
follow up
LTNP (n = 265)
251 (95%)
10 years
195 (74%)
500 cells/µl
96 (36%)
'low/BDL'
153 (58%)
82 (31%)
'stable'
15 (21%)
'stable'
7 (35%)
'stable' 1 (8%)
4 (3%)
'stable' 2 (4%) 2 (6%)
37 (52%) 10 (50%) 9 (69%) 15 (13%) 6 (11%) 1 (3%)
14 (20%)
10 000
copies/ml
1 (5%) 3 (23%) 100 (100%)450 copies/ml
100 (100%)
2000/400
copies/ml
100 (100%)
2 000
copies/ml
51 (72%)
500 cells/µl
12 (60%)
500 cells/µl
10 (77%)
500 cells/µl 22 (19%)
5 (9%)
'high/normal' 5 (16%)
64 (90%)
8 years
12 (60%)
10 years
11 (85%)
10 years
51 (44%)
1 year
39 (72%)
10 years
16 (50%)
1 year
SP (n = 71) LTS (n = 20) NP (n = 13) EC (n = 117) HIC (n = 54) VC (n = 32)
CD4+ count
HIV-RNA
level
Clinical
symptoms
CD4+ slope
Viral control phenotypes
Fig. 4. Predominant components and common thresholds used in definitions of slow progression/viral control terms in
HIV infection. The figure depicts the number of definitions (with proportions in parentheses) for slow progressor/viral control
terms that include specific components and component thresholds as part of the definition. The most frequent component
threshold applied for each of these also represented, where a single common threshold could be identified. BDL, below detection
limit; EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; LTS, long-term survivor; NP, nonprogressor; SP,
slow progressor; VC, viremic controller.
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Table 10, http://links.lww.com/QAD/A415). HIV-
RNA levels and CD4þ cell slopes appeared to be less
prominent components in these definitions.
Nonprogressors
A total of 13 definitions were identified for nonpro-
gressors, of which 11 were unique (Table 4). Duration of
follow-up and CD4þ cell threshold components were
prominent in this group, with 10 years and 500 cells/ml
being the most common thresholds, respectively. HIV-
RNA levels, clinical criteria, and CD4þ cell slopes only
appeared in a minority of definitions (Fig. 4).
Elite controllers
A total of 117 definitions were identified for elite
controllers, of which 50 were unique (Table 4). As
expected from the terminology, HIV-RNA thresholds
appeared in all definitions listed, with thresholds ranging
from 40 to 500 copies/ml (Fig. 4, Supplementary
Table 10, http://links.lww.com/QAD/A415). The most
frequent HIV-RNA threshold used was 50 copies/ml.
Only five definitions included a criterion for occasional
blips in viral load (Fig. 4). Duration of follow-up also
appeared to be important with 44% of definitions
including a minimum duration of follow-up criterion.
Duration thresholds varied from 6 months to 16 years,
with a threshold of 1 year being most frequent
(Supplementary Table 10, http://links.lww.com/QAD/
A415). CD4þ cell thresholds appeared only in 19% of
definitions, in contrast with LTNPs and slow progressors,
wherein 74 and 72% of definitions included this com-
ponent.
HIV controllers
A total of 54 definitions for HICs were identified, of
which 56% were unique (Table 4). All definitions
included a HIV-RNA threshold (Fig. 4). HIV-RNA
thresholds varied from 40 to 10 000 copies/ml, with 400
and 2000 copies/ml both being common thresholds
applied (Supplementary Table 10, http://links.lww.com/
QAD/A415). Duration of follow-up was also an
important component of these definitions, with 72% of
definitions including a cut-off for the minimum duration
of follow-up required (Fig. 4). Thresholds of 10 years and
1 year appeared to be most common for these definitions,
which can be seen as a product of the two most common
definitions of this term (Supplementary Table 10, http://
links.lww.com/QAD/A415, Table 5).
Viremic controllers
Of 32 definitions applied to viremic controllers, the
majority (59%) were unique, suggesting marked varia-
bility in definitions used (Table 4). As with elite
controllers and HICs, all definitions included a HIV-
RNA threshold (Fig. 4). Thresholds were generally
higher in comparison with elite controller definitions and
varied between 500 and 15 000 copies/ml, with a
threshold of 2000 copies/ml being most common (22/
32 definitions; Supplementary Table 10, http://
links.lww.com/QAD/A415). CD4þ cell thresholds
appeared as components in five of 30 definitions, and
there was marked variability in thresholds used (Supple-
mentary Table 10, http://links.lww.com/QAD/A415).
As with elite controllers and HICs, clinical criteria only
appeared in a minority of definitions.
Rapid progressors
Of 90 definitions identified for the terms ‘rapid
progressor’ or ‘fast progressor’, 51 definitions were
unique based on combinations of components considered
(Table 4). CD4þ cell thresholds and AIDS endpoints
appeared to be the most common components of
definitions, with 56% of definitions including a CD4þ
cell endpoint, and 48% of definitions including an AIDS
endpoint (Fig. 5). Among CD4þ cell endpoints, a
threshold of 300 cells/ml was the most frequent (Fig. 5,
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Table 5. Common definitions identified for common terms used to describe extremes in HIV infection.
Term Commonest definitiona Frequency
LTNP Asymptomatic and ART-naive for 10 years during follow-up with all CD4þ cell
counts above 500cells/ml during this period
15/265
SP Seropositive asymptomatic individuals infected for 8 or more years with a CD4þ
T-cell count above 500cells/ml in the absence of ART.
16/71
EC Spontaneously maintain viral loads below 50copies/ml without ART 33/117
HIC HIV-infected patients who had been seropositive for >10 years and had received
no ART for whom >90% of the HIV-RNA measurements were <400 copies/ml
8/54
Alternate definition: HIV-infected individuals with at least three measurements of
plasma HIV-RNA <2000copies/ml over at least a 12-month period in the absence
of ART
7/54
VC Infected with HIV and maintaining viral loads of <2000 RNA copies/ml without
ART
4/32
RP HIV infected with CD4þ T-cell counts of <300cells/ml within 3 years after the
last HIV-seronegative test
17/90
NC HIV-infected individuals with plasma HIV-RNA >10000 copies/ml without ART 6/16
ART, antiretroviral therapy; EC, elite controller; HIC, HIV controller; LTNP, long-term nonprogressor; NC, noncontroller; RP, rapid progressor; SP,
slow progressor; VC, viremic controller.
aSingle dominant definitions could not be identified for long-term survivors and nonprogressors and are, therefore, not presented here.
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Supplementary Table 11, http://links.lww.com/QAD/
A415). Time to end-point was a prominent component
of definitions, with 92% of definitions including a
duration component, the most frequent threshold being
3 years (Fig. 5, Supplementary Table 11, http://links.lww.
com/QAD/A415). Known date of seroconversion
appeared to be a prominent component, with 80% of
definitions including this (Fig. 5). However, many
definitions did not specify time since seroconversion,
including either time from diagnosis or only CD4þ cell
slope-based criteria. HIV-RNA thresholds were rare (6%)
among these definitions (Fig. 5). Death and ART
initiation were also used as endpoints in a small number
of definitions (3% each).
Noncontrollers
There were only 16 definitions of noncontrollers listed,
of which eight were found to be unique based on
combinations of components (Table 4). All definitions
included a HIV-RNA component, with 10 000 copies/ml
being the most common cut-off used (Fig. 5). CD4þ cell
endpoints were also used in two definitions (Fig. 5,
Supplementary Table 11, http://links.lww.com/QAD/
A415), but no clinical endpoints appeared in any
definition.
Common definitions of HIV phenotypes
The most frequently occurring definitions for each term
are listed in Table 5. Single dominant definitions that were
clearly much more common than others could be
identified for most terms, except HICs for whom two
common definitions were identified (Table 5). Although
common definitions are clearly identified for each term, it
can be seen that these still represent the minority of all
definitions listed (Table 5). It is also clear that, although
there are marked differences in the components of
definitions for each term, in most cases specific
component thresholds can be identified for each term
that are far more common than others (Figs. 4 and 5).
Using the most common components and component
threshold/category within components to derive com-
mon definitions produced identical results to those
produced by grouping individual definitions (Figs. 4 and
5 and Table 5). For example, the most common definition
for LTNP was an HIV-infected individual who is
asymptomatic and ART-naive for 10 years during
follow-up with all CD4þ cell counts above 500 cells/ml
during this period, which combines the most common
components and component thresholds/categories listed
for definitions of this term (Fig. 4).
Overlap between definitions
There was substantial overlap between components across
terms, with 36% of LTNP definitions including HIV-
RNA threshold criteria and 19% of elite controller and
16% of viremic controller definitions including CD4þ
cell threshold components (Fig. 4). There was marked
overlap between components and thresholds/categories
used across all slow progression terms, with substantial
overlap between components of LTNPs, slow progressors
and nonprogressors, and between viremic controller and
HICs (Supplementary Table 10, http://links.lww.com/
QAD/A415).
Broad phenotypes represented by different
terms
On the basis of our review, we sought to characterize
the broad HIV phenotypes represented by different terms
in the literature. On considering components and
component thresholds/categories of definitions for
slow progression-related terms, the clinical phenotypes
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Terms (no. of
definitions)
Components
Duration of
follow-up
RP (n = 90) NC (n = 16)
83 (92%)
3 years 0 (0%)
2 (13%)
1 (7%)
16 (100%)
10 000 copies/ml
0 (0%)
0 (0%)
0 (0%)
0 (0%)
41 (56%)
300 cells/µl
10 (11%)
5 (6%)
43 (48%)
3 (3%)
3 (3%)
72 (80%)
CD4+ endpoint
CD4+ slope
HIV-RNA levels
AIDS endpoint
ART endpoint
Death endpoint
Known date of
seroconversion
Fig. 5. Predominant components and common thresholds
used in definitions of rapid progression/noncontroller terms
in HIV infection. The figure depicts the number of definitions
(with proportions in parentheses) for rapid progressor/non-
controller terms that include specific components and com-
ponent thresholds. The most frequent component threshold
applied for each of these also represented, wherein a single
common threshold could be identified. NC, noncontroller;
RP, rapid progressor.
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represented by LTNPs, LTSs, and nonprogressors were
broadly similar, and represented individuals who main-
tained normal CD4þ cell counts, and remained healthy at
least for 10 years of observed follow-up. In general, slow
progressors represented a less stringent phenotype, and
thresholds for duration of follow-up required tended to
be lower (Supplementary Table 10, http://links.lww.
com/QAD/A415). The relative representation of viral
control phenotypes could be broadly characterized, with
elite controllers representing themost extreme phenotype
of viral control, and viremic controllers representing
higher levels of viremia (Fig. 6). For HICs, two broad
phenotypes seemed to predominate: one appeared to be
similar to elite controllers, but with control of viremia to
below 400 copies/ml over at least 10 years, and the second
encompassing elite controller and viremic controller
phenotypes (Fig. 6).
Discussion
In this systematic review, assessing 714 definitions of HIV
extreme phenotypes in 501 eligible studies, we identified
substantial variation among definitions used to describe
extreme phenotypes in HIV infection. This heterogen-
eity in definitions may represent important differences in
biological endophenotypes [14] and clinical progression
profiles [1,22] of individuals selected by these, suggesting
the need for harmonized definitions. In this context, we
were able to identify common components in existing
definitions that may provide a framework for developing
consensus definitions for HIV extreme phenotypes.
Although recent studies have focused on extreme
phenotypes in HIV infection as natural models of viral
control and the extremes of disease progression in HIV,
little is known about the impact of heterogeneity in
definitions on clinical and biological phenotypes cap-
tured. This heterogeneity has implications for the design
of studies exploring HIV biology and for the interpret-
ation of existing research. Although several studies have
referred to this marked variation in definitions, and the
need for standardized phenotype definitions [2,22],
the full extent of variability in the literature has never
been formally quantified. To our knowledge, this is
the first study that has attempted to address this in a
systematic manner. Formal evaluation of the impact of
varying definitions on clinical outcomes and characteriz-
ing biological endophenotypes is essential to develop
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Increased rate of clinical disease progression of HIV infection
LTNP, LTS and NP
EC HIC-1
HIC-2
Decrease host control of virus replication
VC NC
Remain healthy and maintain
stable CD4+ counts above 500
cells/µl for prolonged periods
(usually over ten years)
Spontaneously
maintain
undetectable
HIV RNA levels
(< 50 copies/ml)
without ART
Spontaneously
maintain HIV
RNA levels
< 400
copies/ml
for
at least 10 yrs
Spontaneously
maintain HIV
RNA levels
between 50–
2 000 copies/ml
without ART
Maintain HIV RNA levels
> 10 000 copies/ml in the
absence of ART
Remain healthy and maintain
stable CD4+ counts above 500
cells/µl for prolonged periods
(usually over 8 years)
Rapid immunological or clinical
progression characterised by a
drop in CD4+ counts to < 300
cells/µl within 3 years or
development of AIDS within 3–5
years of infection
SP RP
Fig. 6. Relative characteristics of phenotypes referred to by different terms in the literature. HIC-1 and HIC-2 refer to the two
most commonly used definitions for HIV controllers. ART, antiretroviral therapy; EC, elite controller; HIC, HIV controller; LTNP,
long-term nonprogressor; LTS, long-term survivor; NC, noncontroller; NP, nonprogressor; RP, rapid progressor; SP, slow
progressor; VC, viremic controller.
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harmonized definitions that will represent clinical and
biological phenotypes of interest.
Understanding the impact of variability in phenotype
definitions on clinical outcomes in HIV is important, as
the literature suggests that small variations in phenotype
definitions can substantially impact the trajectory of
disease progression in patients selected. In one study,
varying the duration of follow-up threshold for LTNPs
resulted in the selection of groups with markedly different
survival times [1]. A recent study showed that allowing for
at least one nadir CD4þ cell count below 500 cells/ml
among LTNPs can lead to a significant reduction in the
time to disease progression compared with individuals
who maintain all CD4þ cell counts above this threshold
[22]. This is consistent with research within the French
Hospital Database that showed that a positive CD4þ cell
slope was a more selective criterion than a longer duration
of HIV infection (10 years instead of 8 years), for selecting
patients who were asymptomatic and ART-naive several
years after being infected by HIV [2]. Similar findings
have been demonstrated with viral control phenotypes;
individuals with viral loads less than 50 copies/ml (elite
controllers) have markedly improved AIDS-free survival
compared with individuals with viral loads between 50
and 2000 copies/ml [1]. Prevalence of phenotypes
represented can also vary markedly with small changes
in definitions. For example, in the French Hospital
Database, increasing the CD4þ cell threshold in LTNPs
from 500 to 600 cells/ml changed the prevalence of the
phenotype from 22 to 11% in the cohort, and addition of
a criterion for positive CD4þ cell slope further reduced
the prevalence to 2.8% [2]. This is of particular relevance
to studies that aim to recruit individuals with extreme
phenotypes for further characterization of mechanisms of
immune-virological control.
Variation in extreme phenotype definitions may also
impact on the underlying biological endophenotype
being examined. Our study suggests that there is marked
overlap between components of definitions referring to
different terms in the literature, which makes it difficult to
delineate phenotypes represented by different terms. It is
important to distinguish these terms in the literature, as
different phenotypes may capture different underlying
biology. Indeed, it has been shown that protective and
high-risk alleles known to be associated with disease
control and progression in HIV infection, show a graded
change in frequency along the clinical spectrum of disease
[14]. The limited overlap between LTNP and EC
phenotypes in some studies, with only 8–32% of LTNPs
meeting criteria for elite control [2,22,23], suggests that
slow progression and viral control phenotypes are only
modestly correlated, and may potentially represent
distinct biological phenotypes. A recent genome wide
association study further substantiated this with the
discovery of a new locus associated with LTNP,
when individuals who were EC (HIV-RNA levels
<100 copies/ml) were excluded from the cohort [19],
suggesting that the determinants of viral control and slow
progression phenotypes may be distinct.
Major strengths of our study include the comprehensive
search strategy applied and the large number of articles
reviewed. As the correlation between the studies short-
listed for review by the two reviewers was high (>95%),
there is unlikely to be substantial observer bias in the
review process. We acknowledge that our review of
definitions also has several limitations. Our search strategy
was only restricted to one search engine, to published
articles, and to articles available after the 1 January 2000,
which may have limited the sensitivity of the search.
Additionally, we did not examine definitions by
differences in HIV subtypes and clades, and extreme
phenotypes represented by definitions in these groups
may differ. In spite of these limitations, we believe that
our review is a fair representation of the heterogeneity in
definitions observed in the literature, and the lower
sensitivity of the review would only underestimate
existing heterogeneity among definitions. Moreover, to
our knowledge, this is the first attempt to formally
characterize the variability in definitions of these terms in
literature, and identify common components used to
define these terms.
Given the possible differences in biological and clinical
phenotypes captured by different definitions, it is
important to standardize case definitions of these
phenotypes for consistency in methods and ease of
interpretation across studies. Although the various studies
described have provided clues to the clinical and
biological correlates of different definitions, the literature
examining this is limited and further research specifically
addressing variation in these phenotypes with varying
definitions of phenotypes is essential to develop a
framework for consensus definitions.
Several attributes of definitions must be considered when
formulating consensus definitions. First, phenotype
definitions should capture a truly extreme phenotype,
as sampling from extremes can be a powerful way to
examine HIV biology. This approach has been shown to
be effective [19,24,25] in identifying genetic variants
associated with HIV control and progression. Second,
definitions should represent biologically relevant endo-
phenotypes, so that underlying biology associated with
these can be examined efficiently. Further research
specifically examining the heritability and underlying
biology of different phenotypes is needed in order to
establish which phenotypes are likely to be most
biologically relevant. Third, the phenotype definition
should include components that are clinically relevant and
adequately stable to predict long-term clinical outcomes.
It is also important that the components described can be
easily assessed and data for these can be readily extracted
from existing cohorts. This would require systematic
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assessment of clinical outcomes of commonly used
definitions in large-scale consortia, which have adequate
numbers of these rare individuals, and appropriate data on
seroconversion and detailed clinical outcomes. While
ascertaining the most useful definitions for extreme HIV
phenotypes is challenging, our study shows that in spite of
the large amount of heterogeneity observed in defi-
nitions, common components and thresholds used in
definitions can be identified for most terms, indicating
that there are common threads that have been used to
define these groups in the literature, which could provide
the framework for consensus definitions. Further work
specifically examining the biological characteristics and
differences in clinical progression, among these groups of
individuals is needed in order to inform the utility of
different definitions in HIV research.
Acknowledgements
D.G., K.P., and M.S.S. conceived the study concept and
design. D.G., D.G.D., and L.I. performed the literature
review. D.G. synthesized and analyzed collated data. D.G.
and M.S.S. drafted the article. All authors provided
critical revisions of the article for important intellectual
content. They also acknowledge all members of the UK
HIV Genomics consortium for their contribution to
this work.
The members of UK HIV Genomics Consortium are as
follows:
Wellcome Trust Sanger Institute, Wellcome Trust
Genome Campus, Hinxton, CB10 1SA: D.G., L.I.,
D.G.D., E.Y., Cristina Pomilla, Astrid Gall, Matt Cotten,
Paul Kellam, Manjinder S. Sandhu.
University of Cambridge, Strangeways Research Labora-
tory, University of Cambridge, Cambridge, CB1 8RN:
Deepti Gurdasani, Louise Iles, David G. Dillon, Elizabeth
Young, Cristina Pomilla, Paul Kellam, Manjinder
S. Sandhu.
University College London, London: Paul Kellam.
Medical Research Council, Clinical Trials Unit, Aviation
House, Kingsway 125, London WC2B 6NH: Fiona
Ewings, Ashley Olson, Louise Walker-Nthenda,
Kholoud Porter.
King’s College London, Weston Education Centre, 10
Cutcombe Road, SE5 9RJ, London: Lucy Campbell,
Frank Post
Cambridge University Hospitals NHS Foundation Trust,
Department of Medicine, Box 153, Addenbrooke’s
Hospital, Cambridge, CB2 0QQ: Rhonda Cowie,
Elizabeth Hodges, Effrossyni Gkrania-Klotsas.
University of Oxford, Roosevelt Drive, Headington,
Oxford, OX37BN: Vivek Naranbhai, Frederik Vann-
berg, Adrian Hill.
Homerton University Hospital NHS Foundation Trust,
Homerton row, London E9 6SR: Sifiso Mguni, Jane
Anderson.
Medical Research Council, Uganda Virus Research
Institute, Uganda: Pietro Pala, Pontiano Kaleebu.
Chelsea and Westminster Hospital NHS Foundation
Trust, Chelsea and Westminster Hospital, 369, Fulham
Road, London: Alice Shields, Ruth Bateson, Carl
Fletcher, David Hawkins.
Brighton and Sussex University Hospitals NHS Trust,
BN2 5BE: Laura Waters, Martin Fisher.
Imperial College Healthcare NHS Trust, St. Mary’s
Hospital London, London: Sarah Fidler.
NHS Lothian Trust, Western General Hospital, Edin-
burgh: Sheila Morris, Clifford Leen.
Camden Provider Services, Mortimer Market Centre,
Mortimer Market, London, WC1E 6JB: Richard Gilson.
Royal Free Hampstead NHS Trust, Pond Street, Royal
Free Hospital, London, NW3 2QG: Anne Carroll,
Patrick Bryne, Sabine Kinloch.
The Katharine Dormandy Haemophilia Centre and
Thrombosis Unit, Royal Free Hospital, NW32QG,
London: Thynn Yee.
St George’s Healthcare NHS Trust, Blackshaw Road,
Tooting, SW17 0QT, London: Philip Hay
Sheffield Teaching Hospitals NHS Foundation Trust,
Sheffield: Christine Bowman, Charlie Hughes.
The West London Centre for Sexual Health, Charing
Cross Hospital, Fulham Palace Road, W6 8RF, London:
Ken Mclean.
Portsmouth Hospitals NHS Trust, St. Mary’s Hospital,
GUM Department, Milton Road, Portsmouth, PO3
6AD: Veerakathy Harindra.
St Thomas Hospital, CTU Harrison Wing, Westminster
Bridge Road, London, SE1 7EH: Alice Sharp, Julie Fox.
St Richard’s Hospital, Fletcher Clinic, Chichester, West
Sussex, PO19 6SE: Sam Gamalath.
Extreme phenotypes of HIV control and progression Gurdasani et al. 161
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
East and North Herts NHS Trust, Lister Hospital, Corey’s
Mill Lane, Stevenage, Hertfordshire, SG1 4AB: Elaine
Walker, Deepti Sebastian, K. Udayakumar.
West Hertfordshire Hospitals NHS Trust, Vicarage Road,
Watford, Hertfordshire, WD18: Samantha Hill.
Weatherall Institute of Molecular Medicine, University of
Oxford, Oxford: Linghang Wang, Tao Dong, Sarah
Rowland-Jones.
The present work was partly supported by the Wellcome
Trust Sanger Institute. D.G. was funded by a Cambridge
Commonwealth Scholarship and D.G.D. was funded by
the Gates Foundation Trust. E.G.K. was funded by the
Cambridge Biomedical Research Centre.
Conflicts of interest
There are no conflicts of interest.
References
1. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A,
Ganesan A, et al. Clinical outcomes of elite controllers, viremic
controllers, and long-term nonprogressors in the US Depart-
ment of Defense HIV natural history study. J Infect Dis 2009;
200:1714–1723.
2. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L,
Costagliola D. Prevalence and comparative characteristics of
long-term nonprogressors and HIV controller patients in the
French Hospital Database on HIV. AIDS 2009; 23:1163–1169.
3. Canducci F, Marinozzi MC, Sampaolo M, Berre S, Bagnarelli P,
Degano M, et al. Dynamic features of the selective pressure on
the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-
binding site in a group of long term non progressor (LTNP)
subjects. Retrovirology 2009; 6:4.
4. Diop G, Hirtzig T, Do H, Coulonges C, Vasilescu A, Labib T,
et al. Exhaustive genotyping of the interferon alpha receptor 1
(IFNAR1) gene and association of an IFNAR1 protein variant
with AIDS progression or susceptibility to HIV-1 infection in a
French AIDS cohort. Biomed Pharmacother 2006; 60:569–577.
5. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C,
Delaneau O, et al. Genomewide association study of an
AIDS-nonprogression cohort emphasizes the role played by
HLA genes (ANRS Genomewide Association Study 02). J Infect
Dis 2009; 199:419–426.
6. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P,
et al. Genome-wide mRNA expression correlates of viral con-
trol in CD4R T-cells from HIV-1-infected individuals. PLoS
Pathog 2010; 6:e1000781.
7. Deeks SG, Walker BD. Human immunodeficiency virus con-
trollers: mechanisms of durable virus control in the absence of
antiretroviral therapy. Immunity 2007; 27:406–416.
8. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P,
et al. Receptor-ligand requirements for increased NK cell
polyfunctional potential in slow progressors infected with
HIV-1 coexpressing KIR3DL1Mh/My and HLA-BM57. J Virol
2011; 85:5949–5960.
9. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ,
et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1
p24 epitope in slow progressors with BM57. AIDS 2002;
16:961–972.
10. Zhang Z, Jiang Y, ZhangM, Liu J, SunG, ShiW, et al.Alterations
of CD4(R) CD25(R) Foxp3(R) regulatory T cells in HIV-
infected slow progressors of former blood donors in China.
Microbiol Immunol 2010; 54:625–633.
11. LambotteO, Boufassa F,Madec Y, NguyenA, Goujard C,Meyer
L, et al. HIV controllers: a homogeneous group of HIV-1-
infected patients with spontaneous control of viral replication.
Clin Infect Dis 2005; 41:1053–1056.
12. Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC,
Pollard RB, et al. Increased frequency of regulatory T cells
accompanies increased immune activation in rectal mucosae
of HIV-positive noncontrollers. J Virol 2011; 85:11422–
11434.
13. Fontaine J, Coutlee F, Tremblay C, Routy JP, Poudrier J, RogerM.
HIV infection affects blood myeloid dendritic cells after suc-
cessful therapy and despite nonprogressing clinical disease.
J Infect Dis 2009; 199:1007–1018.
14. Casado C, Colombo S, Rauch A, Martinez R, Gunthard HF,
Garcia S, et al. Host and viral genetic correlates of clinical
definitions of HIV-1 disease progression. PLoS One 2010;
5:e11079.
15. Lajoie J, Fontaine J, Tremblay C, Routy JP, Poudrier J, Roger M.
Persistence of high levels of blood soluble human leukocyte
antigen-G is associated with rapid progression of HIV infec-
tion. AIDS 2009; 23:1437–1440.
16. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI,Walker BD,
et al. The major genetic determinants of HIV-1 control affect
HLA class I peptide presentation. Science 2010; 330:1551–
1557.
17. Walker BD. Elite control of HIV infection: implications for
vaccines and treatment. Top HIV Med 2007; 15:134–136.
18. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of
HIV infection: implications for vaccine design. Expert Opin Biol
Ther 2009; 9:55–69.
19. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le
Clerc S, et al. Multiple-cohort genetic association study
reveals CXCR6 as a new chemokine receptor involved in
long-term nonprogression to AIDS. J Infect Dis 2010; 202:
908–915.
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting
items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med 2009; 6:e1000097.
21. Knapp S, Lenz P, Gerlitz S, Rieger A, Meier S, Stingl G. Highly
active antiretroviral therapy responders exhibit a phenotypic
lymphocyte pattern comparable to that of long-term nonpro-
gressors. Int Arch Allergy Immunol 2001; 126:248–256.
22. Mandalia S,Westrop SJ, Beck EJ, NelsonM, Gazzard BG, Imami
N. Are long-term nonprogressors very slow progressors? In-
sights from the Chelsea andWestminster HIV cohort. PLoSOne
2012; 7:e29844.
23. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A,
Boucherit S, et al. Early control of HIV-1 infection in long-term
nonprogressors followed since diagnosis in the ANRS SERO-
CO/HEMOCO cohort. J Acquir Immune Defic Syndr 2009;
50:19–26.
24. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M,
O’Brien S, Andrieu JM, et al. New class I and II HLA alleles
strongly associated with opposite patterns of progression to
AIDS. J Immunol 1999; 162:6942–6946.
25. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F,
Zagury JF. 32bp CCR-5 gene deletion and resistance to fast
progression in HIV-1 infected heterozygotes. Lancet 1997;
349:922–923.
162 AIDS 2014, Vol 28 No 2
